2024
Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial management
2023
Moving toward disease modification in polycythemia vera
Bewersdorf J, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal R. Moving toward disease modification in polycythemia vera. Blood 2023, 142: 1859-1870. PMID: 37729609, DOI: 10.1182/blood.2023021503.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaProgression to myelofibrosisPolycythemia veraCytoreductive therapyBCR-ABL1-negative myeloproliferative neoplasmsLow-risk PVLow-risk diseaseHistory of thrombosisHigh-risk diseaseDisease-modifying treatment modalitiesAssociated with higher ratesEvolving treatment landscapeClinically meaningful outcome measuresDisease-related symptomsInterferon alfaMyeloproliferative neoplasmsThromboembolic eventsPatient ageMyeloid leukemiaTreatment modalitiesIFN-a2bTherapeutic phlebotomyActivating mutationsVasomotor symptomsDisease courseClinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)
Tentori C, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Berrocal J, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao L, Bernardi M, Di Grazia C, Vago L, Rivoli G, Borin L, Chiusolo P, Giaccone L, Voso M, Bewersdorf J, Nibourel O, Díaz-Beyá M, Jerez A, Hernandez F, Kennedy K, Xicoy B, Ubezio M, Campagna A, Russo A, Todisco G, Mannina D, Bramanti S, Zampini M, Riva E, Bicchieri M, Asti G, Viviani F, Buizza A, Tinterri B, Bacigalupo A, Rambaldi A, Passamonti F, Ciceri F, Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kordasti S, Santini V, Sanz G, Kern W, Kubasch A, Platzbecker U, Diez-Campelo M, Maciejewski J, Ades L, Fenaux P, Haferlach T, Zeidan A, Castellani G, Komrokji R, Ieva F, Della Porta M. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS). Blood 2023, 142: 197. DOI: 10.1182/blood-2023-182194.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationStem cell transplantationMyelodysplastic syndromeProlonged life expectancyClinical outcomesOptimal timingCell transplantationLife expectancyValidation cohortImmediate transplantationTransplantation policyRisks of HSCTImmediate hematopoietic stem cell transplantationAllogeneic hematopoietic stem cell transplantationAge groupsDiagnosis of MDSConventional prognostic scoresPost-HSCT outcomesLow-risk diseaseTiming of transplantationDisease-modifying therapiesEarly disease stagesPatient's life expectancyAverage survival timeDifferent time pointsProstate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsySupportive Care for Patients With Myelodysplastic Syndromes
Stempel J, Podoltsev N, Dosani T. Supportive Care for Patients With Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 168-178. PMID: 37195773, DOI: 10.1097/ppo.0000000000000661.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeMyeloid leukemiaLow-risk diseaseTreatment-related complicationsSupportive care interventionsSupportive care measuresAcute myeloid leukemiaBone marrow disordersAntimicrobial prophylaxisFrequent complicationProgressive cytopeniasSupportive careTransfusion supportHigh-risk counterpartsBetter prognosisPalliative careRoutine immunizationCare measuresCare interventionsIneffective hematopoiesisIron overloadCommon causeMarrow disordersSyndrome populationPatientsConsiderations for Drug Development in Myelodysplastic Syndromes
Sekeres M, Kim N, DeZern A, Norsworthy K, Garcia J, de Claro R, Theoret M, Jen E, Ehrlich L, Zeidan A, Komrokji R. Considerations for Drug Development in Myelodysplastic Syndromes. Clinical Cancer Research 2023, 29: 2573-2579. PMID: 36688922, PMCID: PMC10349686, DOI: 10.1158/1078-0432.ccr-22-3348.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeTrial designDrug developmentResponse criteriaLow-risk diseaseHigh-risk patientsFuture trial designClinical trial designQuality of lifeValidation of PatientHigh-need populationDurable responsesOverall survivalAnemic patientsTransfusion dependencyClinical benefitPatient populationAdvanced ageClinical trialsDose reductionOutcome instrumentsNew therapiesPreclinical modelingPatientsActive drugAdvances in myelodysplastic syndromes: promising novel agents and combination strategies
Madanat Y, Xie Z, Zeidan A. Advances in myelodysplastic syndromes: promising novel agents and combination strategies. Expert Review Of Hematology 2023, 16: 51-63. PMID: 36620919, DOI: 10.1080/17474086.2023.2166923.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHigh-risk myelodysplastic syndromeMultiple novel agentsMyelodysplastic syndromeNovel agentsClinical trialsTreatment optionsPhase III clinical trialsSelect clinical trialsLow-risk diseaseClonal hematopoietic stem cell neoplasmHigh-risk diseaseBest treatment optionHematopoietic stem cell neoplasmsInnate immune systemStem cell neoplasmMechanism of actionHMA therapyEarly safetyTreatment paradigmEfficacy dataCell neoplasmsDrug combinationsClinical developmentUnmet needImmune system
2021
Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance
Ullrich SJ, Worhunsky D, Rodwin R, Pashankar F, Christison-Lagay E, Ozgediz D. Pulmonary Metastasis of Low-risk Perinatal Neuroblastoma After Resection: Implications for Surveillance. Journal Of Pediatric Hematology/Oncology 2021, 43: e184-e186. PMID: 31815890, DOI: 10.1097/mph.0000000000001693.Peer-Reviewed Case Reports and Technical Notes
2020
Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).
Ferris R, Flamand Y, Weinstein G, Li S, Quon H, Mehra R, Garcia J, Chung C, Gillison M, Duvvuri U, O'malley B, Ozer E, Thomas G, Koch W, Kupferman M, Bell R, Saba N, Lango M, Mendez E, Burtness B. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). Journal Of Clinical Oncology 2020, 38: 6500-6500. DOI: 10.1200/jco.2020.38.15_suppl.6500.Peer-Reviewed Original ResearchProgression-free survivalExtranodal extensionOropharynx cancerTransoral resectionPrimary endpointArm BArm AECOG-ACRIN Cancer Research GroupAdvanced oropharynx cancerTreatment-related deathsUninvolved surgical marginsArm DIntermediate-risk patientsLow-risk diseasePhase III trialsNon-surgical therapyGood oncologic outcomesPost-operative managementCancer Research GroupPost-operative therapyLow-dose radiationPostoperative RTDistant recurrenceFree survivalIII trialsCui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes
Shallis RM, Podoltsev NA, Gowda L, Zeidan AM, Gore SD. Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. Expert Review Of Hematology 2020, 13: 447-460. PMID: 32182435, DOI: 10.1080/17474086.2020.1744433.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAllogeneic stem cell transplantationStem cell transplantationAcute myeloid leukemiaMyelodysplastic syndromeMDS patientsRisk stratificationCell transplantationPrognostic toolLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeLow-risk MDS patientsSevere bone marrow failureLow-risk diseaseLow-risk patientsOnly curative optionPrognosis of patientsBone marrow failureAggressive therapyCurative optionPrognostic impactEtiologic roleDisease progressionMyeloid leukemiaAlloSCTPatients
2019
Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.
Dinan MA, Wilson LE, Reed SD. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal Of The National Comprehensive Cancer Network 2019, 17: 245-254. PMID: 30865923, DOI: 10.6004/jnccn.2018.7097.Peer-Reviewed Original ResearchConceptsLow-risk diseaseHigh-risk patientsHigh-risk diseaseRS testingMedicare beneficiariesPrimary analysisEstrogen receptor-positive breast cancerReceptor-positive breast cancerLower chemotherapy useIntermediate-risk diseaseIntermediate-risk patientsRetrospective cohort studyGenomic testingSEER-Medicare dataChemotherapy useCohort studyMultivariable analysisBreast cancerChemotherapy costsLow overall useMAIN OUTCOMEMedicare populationPatientsHigher overall costsDisease
2018
Percutaneous Management of Upper Tract Urothelial Carcinoma
Pan S, Motamedinia P. Percutaneous Management of Upper Tract Urothelial Carcinoma. 2018, 384-389. DOI: 10.1002/9781119245193.ch31.ChaptersUpper tract urothelial carcinomaUrothelial carcinomaLow-risk diseaseRare urologic malignancyStandard retrograde approachPatient risk stratificationPercutaneous tumor resectionRadical surgeryRisk stratificationTreatment algorithmAccurate stagingPercutaneous managementUrologic malignanciesTumor resectionBladder cancerRetrograde approachBiopsy capabilityPatientsCarcinomaDiseaseResectionSurgeryMalignancyCancerStaging
2016
Upgrading and upstaging at radical prostatectomy in the post–prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection?
Edmund L, Rotker KL, Lakis NS, Brito JM, Lepe M, Lombardo KA, Renzulli JF, Matoso A. Upgrading and upstaging at radical prostatectomy in the post–prostate-specific antigen screening era: an effect of delayed diagnosis or a shift in patient selection? Human Pathology 2016, 59: 87-93. PMID: 27720731, DOI: 10.1016/j.humpath.2016.09.017.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiopsy, NeedleCytoreduction Surgical ProceduresDelayed DiagnosisEarly Detection of CancerHumansKallikreinsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPatient SelectionPredictive Value of TestsProstatectomyProstate-Specific AntigenProstatic NeoplasmsTime FactorsWatchful WaitingConceptsGroup 2Group 1Group 3Needle biopsyActive surveillanceProstate-specific antigen (PSA) screeningPathologic stage pT3Radical prostatectomy findingsLow-risk diseaseGleason score 4High-risk diseaseGleason score 8Prostate needle biopsyProstate cancer managementProstatectomy findingsCytoreductive surgeryStage pT3Screening eraMore patientsPatient selectionAntigen screeningScore 8Radical prostatectomyGleason 6Cancer managementEmerging Technologies and Techniques in Radiation Therapy
Magnuson W, Mahal A, Yu J. Emerging Technologies and Techniques in Radiation Therapy. Seminars In Radiation Oncology 2016, 27: 34-42. PMID: 27986210, DOI: 10.1016/j.semradonc.2016.08.004.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyHigh-dose-rateProton beam radiationRadiation therapyProstate cancerHigh-dose-rate (HDR) brachytherapyHigh-risk prostate cancer patientsHigh-risk prostate cancerTreatment of prostate cancerPartial gland treatmentProstate-directed therapyRegional radiation therapyLow-risk diseaseBeam radiationProstate cancer patientsDeliver radiationImprove cancer controlHigh-Intensity Focused UltrasoundFocal therapyTherapeutic modalitiesRadiation treatmentCancer patientsCancer controlTherapyReduced toxicityPathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy
Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.Peer-Reviewed Original ResearchConceptsAfrican American raceLow-risk prostate cancerAfrican American menRisk prostate cancerCaucasian manProstate cancerPathological upgradingBiochemical recurrenceFive-year recurrence-free survival ratesClinical low‐risk prostate cancerClinical low-risk diseaseRecurrence-free survival ratesCox proportional hazards analysisBiochemical recurrence outcomesEqual-access health systemLow-risk diseaseCohort of patientsLow-risk tumorsPositive surgical marginsProportional hazards analysisSearch databasesSEARCH cohortRecurrence outcomesRisk diseaseRisk tumorsA Case for Nephron Sparing Surgery in the Management of Upper Tract Urothelial Carcinoma
Motamedinia P, Hoenig D, Okeke Z, Smith A. A Case for Nephron Sparing Surgery in the Management of Upper Tract Urothelial Carcinoma. Journal Of Endourology 2016, 30: s-18-s-22. PMID: 26872591, DOI: 10.1089/end.2015.0822.Peer-Reviewed Original ResearchConceptsUpper tract urothelial carcinomaUrothelial carcinomaLow-risk diseaseRenal function preservationFirst-line treatmentNephron sparing surgeryOncologic outcomesRadical nephroureterectomyDistal ureterectomySparing surgeryRisk diseaseFunction preservationTreatment algorithmSelect casesUTUC treatmentCarcinomaTreatmentNephroureterectomyUreterectomyManagementPatientsSurgeryCost savingsDiseaseNephronChemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population. Journal Of Clinical Oncology 2016, 34: 32-32. DOI: 10.1200/jco.2016.34.7_suppl.32.Peer-Reviewed Original ResearchHigh-risk diseaseOncotype DXRisk diseaseChemotherapy costsODX testingBreast cancerAdjuvant chemotherapyRisk womenPatient outcomesEnd Results-Medicare dataEarly-stage breast cancerER-positive breast cancerReal-world clinical practiceIntermediate-risk womenSEER-Medicare populationLow-risk diseaseHigh-risk womenPositive breast cancerWorld clinical practiceActual patient outcomesTotal Medicare paymentsNCCN guidelinesOverall cohortMultivariable analysisPathologic featuresPathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy.
Leapman M, Freedland S, Aaronson W, Kane C, Terris M, Amling C, Carroll P, Cooperberg M. Pathologic and biochemical outcomes among African American and Caucasian men with low-risk prostate cancer in the search database: Implications for active surveillance candidacy. Journal Of Clinical Oncology 2016, 34: 76-76. DOI: 10.1200/jco.2016.34.2_suppl.76.Peer-Reviewed Original ResearchBiochemical recurrenceAA raceCaucasian manProstate cancerAA menCaucasian raceEqual Access Regional Cancer Hospital (SEARCH) databaseClinical low-risk diseaseLow-risk prostate cancerRecurrence-free survival ratesCox proportional hazards analysisAdverse pathological findingsEqual-access health systemHigher median PSAImmediate radical prostatectomyLow-risk diseaseLow-risk tumorsPositive surgical marginsProportional hazards analysisLow-risk menAfrican American menUse of ASGleason upgradePathologic upgradingPathological upgrade
2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapyPresence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer
Adam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer. Journal Of Clinical Oncology 2015, 33: 2370-2375. PMID: 26077238, DOI: 10.1200/jco.2014.59.8391.Peer-Reviewed Original ResearchConceptsCervical lymph node metastasisAge 45 yearsLymph node metastasisPapillary thyroid cancerMetastatic lymph nodesAmerican Joint CommitteeOverall survivalNode metastasisMetastatic nodesLymph nodesNodal metastasisThyroid cancerJoint CommitteeAssociation of OSPatients age 45 yearsNational Cancer Data BaseCurrent American Joint CommitteeMore positive nodesLow-risk diseasePresence of lymphAdditional mortality riskPositive nodesPreoperative screeningAdult patientsSEER database
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply